Compare DLPN & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | INTS |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 13.7M |
| IPO Year | 2008 | 2021 |
| Metric | DLPN | INTS |
|---|---|---|
| Price | $1.19 | $4.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | 8.6K | ★ 29.3K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.87 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $56,699,389.00 | N/A |
| Revenue This Year | $14.73 | N/A |
| Revenue Next Year | $7.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.70 | N/A |
| 52 Week Low | $1.02 | $0.22 |
| 52 Week High | $1.88 | $8.06 |
| Indicator | DLPN | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 42.07 |
| Support Level | $1.06 | $3.95 |
| Resistance Level | $1.20 | $5.09 |
| Average True Range (ATR) | 0.05 | 0.25 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 16.60 | 4.24 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing, and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials. The company operates within the U.S.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.